VFY
VITRAFY LIFE SCIENCES LIMITED
$2.55
▲ +10.87%
Market cap
$159M
Turnover
$90,998
Last price
$2.55
Day change
+10.87%
Announcements
17
Range, past year
Open 1.520 · Low 1.160 · Now 2.550 · High 4.660
Open VFY in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
VFY momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
40/100
Wyckoff phase
Accumulation10d
Trend stage
Neutral
1 Day
+10.9%
1 Week
+9.4%
1 Month
-10.8%
1 Year
+59.4%
RSI
48
Avg daily range
7.3%
VITRAFY LIFE SCIENCES LIMITED scores 40 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 10 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.84 — highly linear uptrend
Points to watch
- 60d drawdown -47.1%
- High volatility (ATR 7.3%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
VFY announcements
Recent price-sensitive releases.
- 2026-10-28 Q1 FY27 Quarterly Activities Report and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-30 Vitrafy enters partnership with Versiti Blood Health Progress Report
- 2026-09-02 Vitrafy enters U.S. Cell & Gene Therapy Market Progress Report
- 2026-08-04 FY26 Full Year Results Presentation Company Presentation | Preliminary Final Report
- 2026-08-04 FY26 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-29 Q4 FY26 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-23 Vitrafy enters a partnership with Hoxworth Blood Center
More Health Care stocks
Most traded in the same sector.